ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

2016 American Transplant Congress » Poster Session B: Drug Minimization

Date: Sunday, June 12, 2016

Time: 6:00pm-7:00pm

Location: Halls C&D

Session Type: Poster Session

Meeting: 2016 American Transplant Congress

6:00pm-7:00pm
A Comprehensive Biomarker Study to Compare Tacrolimus and Mycophenolic Acid versus Half-Dose Tacrolimus and Everolimus in De Novo Kidney Transplant Patients in the Novartis US92 Study.

J. Klepacki,1 J. Klawitter,1 J. Klawitter,1 A. Karimpour-fard,2 E. Anderson,1 G. Ingle,3 D. Patel,3 K. Johnson,4 D. Cibrik,4 U. Christians.1

6:00pm-7:00pm
A Randomized-Controlled Trial Comparing the Efficacy of CYP3A5 Genotype-Based with Bodyweight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation.

N. Shuker,1,2 R. Bouamar,2 R. van Schaik,3 M. Clahsen -van Groningen,4 J. Damman,5 C. Baan,1 J. van de Wetering,1 A. Rowshani,1 W. Weimar,1 T. van Gelder,1,2 D. Hesselink.1

6:00pm-7:00pm
A Weighted Approach to Composite Efficacy Analysis in Kidney Transplantation.

B. Kaplan, K. MaCague, D. Patel, F. Vincenti.

6:00pm-7:00pm
Advantages of Computerized Dosing Strategy in Tacrolimus Treatment of Renal Transplant Patients.

S.-Y. Kim,1 S. Cho,1 M.-J. Cho,1 C. Lee,1 A. Han,1 C. Choi,1 S. Ahn,1 S.-I. Min,1 S.-K. Min,1 M. Park,2 I. Jung,3 S. Kim,4 J. Ha.1,2

6:00pm-7:00pm
Benefit of Mycophenolate Mofetile Addition to Very Low Exposure Everolimus and Calcineurine Inhibitor Based Immunosuppression in De Novo Kidney Transplantation with 2 Years Follow-Up.

Y. Watarai,1 M. Okada,1 K. Futamura,1 T. Nagai,1 T. Yamamoto,1 M. Tsujita,1 T. Hiramitsu,1 N. Goto,1 S. Narumi,1 T. Kobayashi.2

6:00pm-7:00pm
Clinical Factors That Determine the Appropriateness of Early Steroid Withdrawal.

S. Bae, A. Massie, S. DiBrito, X. Luo, L. Kucirka, D. Segev.

6:00pm-7:00pm
Clinical Outcomes of Simplified Once-Daily Immunosuppressive Regimen for Kidney Recipients.

C.-K. Oh,1 S.-J. Kim,2 K. Huh,3 S. Kim,4 H. Cho,5 S. Lee.6

6:00pm-7:00pm
Comparison of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients.

Y. Watarai,1 M. Okada,1 K. Futamura,1 T. Nagai,1 T. Yamamoto,1 M. Tsujita,1 T. Hiramitsu,1 N. Goto,1 S. Narumi,1 T. Kobayashi.2

6:00pm-7:00pm
Comparison of Transplant Outcomes for Low-Dose and Standard-Dose Tacrolimus in Kidney Transplant Recipients.

J.-H. Cho, K. Kim, M. Kim, W. Do, Y. Yang, T. Yim, I. Hwang, J.-H. Lee, E. Kwon, H.-Y. Jung, J.-Y. Choi, S.-H. Park, Y.-L. Kim, C.-D. Kim.

6:00pm-7:00pm
Do We Need an Individually Tailored Immunosuppression Strategy for Living Donor Kidney Transplant Recipients with PreTransplant Donor Specific Antibodies? A Retrospective Analysis.

S. Bhutani,1 A. Ponnusamy,2 Q. Tak,1 S. Shah,1 J. Worthington,1 A. Summers,1 K. Poulton,1 D. Van Dellen,1 M. Morton,1 M. Picton.1

6:00pm-7:00pm
Elderly Kidney Transplant Recipients Need Optimized Immunosuppression According to Comorbidity and Infection.

E. Kang,1 S. Park,1 S. Park,1 S. Yang,2 I. Jung,3 S.-K. Park,4 Y. Kim,5 D.-J. Han,1 Y. Kim,1 J. Lee.6

6:00pm-7:00pm
Evaluation According to Donor Source: 24-Month Results from Post-Hoc Analysis of the ELEVATE Study in Kidney Transplant Recipients.

J. de Fijter, H. Holdaas, P. Lopez, P. Bernhardt, D. Gaohong, J. Cruzado, M. van der Giet.

6:00pm-7:00pm
Evaluation of an Early Steroid Withdrawal Maintenance Regimen in African American Renal Transplant Recipients.

S. Gabardi, M. Kim, R. Alsheikh, K. Townsend, A. Chandraker.

6:00pm-7:00pm
Everolimus and Low Dose Cyclosporine Immunosuppressive Regimen and Development of Anti HLA Donor Specific Antibodies.

E. Minetti,1 L. Di Maria,1 L. Caroti,1 E. Buti,2 P. Carta.1

6:00pm-7:00pm
High Tacrolimus Dose Requirements at Month 6 Are Associated with Inferior Graft Function in Renal Transplant Patients.

O. Rissling, S. Brakemeier, L. Lehner, F. Halleck, O. Staeck, D. Schmidt, K. Budde.

6:00pm-7:00pm
How Tacrolimus Variability Affects Donor Specific Antibodies, Rejection and Outcome After Kidney Transplantation.

S. Papachristos, A. John Velvet, A. Summers, A. Tavakoli, R. Dhanda, R. Pararajasingam, B. Forgacs.

6:00pm-7:00pm
Impact of Ethnicity on Tacrolimus Trough/Dose Ratios Following Solid Organ Transplantation.

A. Santeusanio, A. Owusu-Obeng, J. Jeff.

6:00pm-7:00pm
Impact of HLA-DR Compatibility on Efficacy Outcomes and Renal Function in Kidney Transplant Recipients Following Early Switch from Calcineurin Inhibitor to Everolimus: Subanalysis from the ELEVATE Study.

J. Cruzado, H. Holdaas, P. Lopez, J. Aguilar, G. Dong, F. Claas, W. Arns, M. van der Giet, J. de Fijter.

6:00pm-7:00pm
Impact on Wound Healing Events After Early Conversion to Everolimus in De Novo Renal Transplant Recipients: 24-Month Results from the Randomized ELEVATE Study.

B. Nashan,1 M. van der Giet,1 H. Holdaas,1 M. Zeier,1 J. Pascual,1 Y. Avihingsanon,1 P. Lopez,2 J. Aguilar-Sanchez,2 J. Kochuparampil,2 Z. Wang,3 J. Cruzado,1 J. De Fijter.1

6:00pm-7:00pm
Long-Term Efficacy and Safety of Everolimus Based Immunosuppression on De Novo Kidney Transplantation with 7 Years Follow-Up.

Y. Watarai, M. Okada, K. Futamura, T. Nagai, T. Yamamoto, M. Tsujita, T. Hiramitsu, N. Goto, S. Narumi, T. Kobayashi.

6:00pm-7:00pm
Outcomes of Hispanic Kidney Transplant Recipients Under a Cyclosporine versus Tacrolimus Based Immunosuppression Protocol.

P. West-Thielke, A. Lasky, J. Thielke, M. Campara, E. Benedetti.

6:00pm-7:00pm
Pediatric Patients Benifit from Steroids Free Regimen After Kidney Transplantation: A Meta-Analysis.

R. Deng, H. Zhang, Y. Zheng, L. Liu, C. Wang.

6:00pm-7:00pm
Prospective Randomized Study of a Steroid Free, Low Dose Tacrolimus with Everolimus Regimen in Kidney Transplant.

A. Shetty, O. Traitanon, M. Ansari, J. Mathew, J. Leventhal, V. Mas, L. Gallon.

6:00pm-7:00pm
Quadruple Induction Regimen with Basiliximab, Everolimus, Mycophenolate and Very Low Dose Tacrolimus Improves Graft Function without Increase in the Incidence of Microvascular Inflammation or De Novo Donor Specific Antibody Compared to the Standard Triple Regimen.

M. Miura, H. Higashiyama.

6:00pm-7:00pm
Rapid Discontinuation of Prednisone (RDP) in Kidney Transplant (KTx) Recipients: 15-Year Outcomes.

O. Serrano,1 R. Kandaswamy,1 K. Gillingham,1 W. Payne,1 T. Dunn,1 S. Chinnakotla,1 E. Finger,1 H. Ibrahim,2 A. Kukla,2 R. Spong,2 N. Issa,2 T. Pruett,1 A. Matas.1

6:00pm-7:00pm
Renal Dysfunction at 12 Months Is Not Associated with Everolimus Exposure in De Novo Renal Transplant Recipients.

F. Shihab,1 Y. Qazi,2 S. Mulgaonkar,3 K. McCague,4 D. Patel,4 V. Peddi,5 D. Shaffer.6

6:00pm-7:00pm
Role of Induction Therapy in Low Immune Risk Kidney Transplant Recipients.

B. Chopra, K. Sureshkumar.

6:00pm-7:00pm
Significant Pharmacokinetic Interaction Between Everolimus and Tacrolimus in De Novo Renal Transplant Recipients.

H.-P. Chang,1 C.-Y. Lee,2 C.-C. Si,1 M.-K. Tsai,2 F.-L. Lin Wu.1,3

6:00pm-7:00pm
Steroid Free Immunosuppression and Clinical Outcomes in Recipients of Deceased Donor Kidney Transplant with Positive Flow Cytometry Crossmatch.

O. Adebiyi, T. Taber, W. Goggins, D. Mishler, M. Yaqub, A. Sharfuddin.

6:00pm-7:00pm
Stratification of Kidney Transplant Recipients into Those with Low and High Alloreactive T-Cells May Allow Safe Conversion to mTOR-Inhibitor-Based Immunosuppression.

T. Schachtner,1,2 M. Stein,2 P. Reinke.1,2

6:00pm-7:00pm
TRANSFORM: A Modern Approach to Evaluate Long-Term Outcomes of Everolimus with Reduced-Calcineurin Inhibitors in De Novo Kidney Transplant Recipients[mdash]Baseline Characteristics.

M. Henry.

6:00pm-7:00pm
The BEST Trial: A Prospective Randomized Trial of Belatacept-Based, CNI- and Corticosteroid-Free Immunosuppression.

E. Woodle,1 D. Kaufman,2 A. Shields,1 J. Leone,3 A. Matas,4 A. Wiseman,5 P. Thielke,6 R. Alloway.1

« View all sessions from the 2016 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences